Cyclosporine for SJS/TEN: a case series and review of the literature.
D Reese, JS Henning, K Rockers, D Ladd, R Gilson - Cutis, 2011 - europepmc.org
D Reese, JS Henning, K Rockers, D Ladd, R Gilson
Cutis, 2011•europepmc.orgClear guidelines for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are lacking due to its infrequency and the absence of large controlled
studies. Systemic corticosteroids and intravenous immunoglobulin (IVIG) have received
considerable attention, though reports of the use of these agents have demonstrated mixed
success rates in improving morbidity and mortality from SJS/TEN. We present a case series
of 4 patients with SJS/TEN who rapidly responded to treatment with cyclosporin A (CsA). We …
necrolysis (TEN) are lacking due to its infrequency and the absence of large controlled
studies. Systemic corticosteroids and intravenous immunoglobulin (IVIG) have received
considerable attention, though reports of the use of these agents have demonstrated mixed
success rates in improving morbidity and mortality from SJS/TEN. We present a case series
of 4 patients with SJS/TEN who rapidly responded to treatment with cyclosporin A (CsA). We …
Clear guidelines for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are lacking due to its infrequency and the absence of large controlled studies. Systemic corticosteroids and intravenous immunoglobulin (IVIG) have received considerable attention, though reports of the use of these agents have demonstrated mixed success rates in improving morbidity and mortality from SJS/TEN. We present a case series of 4 patients with SJS/TEN who rapidly responded to treatment with cyclosporin A (CsA). We discuss the proposed mechanism of action and the rationale for the use of cyclosporin based on the currently understood pathophysiologic mechanism of TEN.
europepmc.org